EWTX
NASDAQEdgewise Therapeutics Inc.
News · 26 weeks64+200%
2026-03-012026-08-23
Mix4190d
- Insider20(49%)
- Other11(27%)
- SEC Filings8(20%)
- Analyst1(2%)
- M&A1(2%)
Latest news
25 items- PREdgewise Therapeutics Announces Upcoming Late-Breaking Science Presentation at the European Society of Cardiology (ESC) Congress 2026– Presentation highlights positive top-line data from 12-week Phase 2 CIRRUS-HCM trial with EDG-7500 in obstructive and nonobstructive hypertrophic cardiomyopathy (HCM) –BOULDER, Colo., Aug. 24, 2026 /PRNewswire/ -- Edgewise Therapeutics, Inc. (NASDAQ:EWTX), a leading clinical-stage biopharmaceutical company focused on cardiovascular diseases, today announced that the CIRRUS-HCM abstract was selected for a late-breaking science presentation at the European Society of Cardiology (ESC) Congress, taking place August 28-31 in Munich, Germany. EDG-7500 is a novel, oral, selective cardiac sarcomere modulator designed to slow early contraction and improve cardiac relaxation in symptomatic HCM while
- INSIDERAmendment: SEC Form 4 filed by Chief Financial Officer Nofi Michael4/A - Edgewise Therapeutics, Inc. (0001710072) (Issuer)
- INSIDERAmendment: SEC Form 4 filed by CMO Donovan Joanne M.4/A - Edgewise Therapeutics, Inc. (0001710072) (Issuer)
- INSIDERAmendment: SEC Form 4 filed by Chief Scientific Officer Russell Alan J4/A - Edgewise Therapeutics, Inc. (0001710072) (Issuer)
- INSIDERAmendment: SEC Form 4 filed by General Counsel Moore John R4/A - Edgewise Therapeutics, Inc. (0001710072) (Issuer)
- INSIDERAmendment: SEC Form 4 filed by Chief Business Officer Derakhshan Behrad4/A - Edgewise Therapeutics, Inc. (0001710072) (Issuer)
- INSIDERSEC Form 4 filed by Chief Financial Officer Nofi Michael4 - Edgewise Therapeutics, Inc. (0001710072) (Issuer)
- INSIDERGeneral Counsel Moore John R converted options into 12,499 shares and sold $219,823 worth of shares (5,016 units at $43.82), increasing direct ownership by 73% to 17,697 units (SEC Form 4) (for tax liability)4 - Edgewise Therapeutics, Inc. (0001710072) (Issuer)
- INSIDERCMO Donovan Joanne M. converted options into 12,812 shares and sold $412,703 worth of shares (9,441 units at $43.71) as part of a pre-agreed trading plan, increasing direct ownership by 64% to 8,625 units (SEC Form 4) (for tax liability)4 - Edgewise Therapeutics, Inc. (0001710072) (Issuer)
- INSIDERChief Scientific Officer Russell Alan J converted options into 12,812 shares and sold $258,042 worth of shares (5,901 units at $43.73), increasing direct ownership by 28% to 31,466 units (SEC Form 4) to satisfy withholding obligation4 - Edgewise Therapeutics, Inc. (0001710072) (Issuer)
- INSIDERChief Business Officer Derakhshan Behrad converted options into 13,281 shares and sold $223,424 worth of shares (5,100 units at $43.81), increasing direct ownership by 35% to 31,826 units (SEC Form 4) to cover taxes4 - Edgewise Therapeutics, Inc. (0001710072) (Issuer)
- INSIDERPresident and CEO Koch Kevin converted options into 39,844 shares and sold $785,042 worth of shares (17,971 units at $43.68), increasing direct ownership by 71% to 52,488 units (SEC Form 4) (withholding obligation)4 - Edgewise Therapeutics, Inc. (0001710072) (Issuer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Edgewise Therapeutics Inc.SCHEDULE 13G/A - Edgewise Therapeutics, Inc. (0001710072) (Subject)
- SECSEC Form 144 filed by Edgewise Therapeutics Inc.144 - Edgewise Therapeutics, Inc. (0001710072) (Subject)
- SECSEC Form SCHEDULE 13G filed by Edgewise Therapeutics Inc.SCHEDULE 13G - Edgewise Therapeutics, Inc. (0001710072) (Subject)
- SECEdgewise Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Edgewise Therapeutics, Inc. (0001710072) (Filer)
- SECSEC Form 10-Q filed by Edgewise Therapeutics Inc.10-Q - Edgewise Therapeutics, Inc. (0001710072) (Filer)
- PREdgewise Therapeutics Reports Second Quarter 2026 Financial Results– Announced positive top-line data from 12-week Phase 2 CIRRUS-HCM trial with EDG-7500 in obstructive and nonobstructive hypertrophic cardiomyopathy (HCM) –– Completed sale of sevasemten and muscular dystrophy business to Servier for up to $2.65 billion in July 2026, strengthening the balance sheet, sharpening focus on the cardiovascular pipeline –BOULDER, Colo., Aug. 6, 2026 /PRNewswire/ -- Edgewise Therapeutics, Inc. (NASDAQ:EWTX), a leading clinical-stage biopharmaceutical company focused on cardiovascular diseases, today reported financial results for the second quarter of 2026 and recent business highlights. "In the seco
- INSIDERSEC Form 4 filed by Director Root Jonathan D4 - Edgewise Therapeutics, Inc. (0001710072) (Issuer)
- SECAmendment: Edgewise Therapeutics Inc. filed SEC Form 8-K: Financial Statements and Exhibits8-K/A - Edgewise Therapeutics, Inc. (0001710072) (Filer)
- SECEdgewise Therapeutics Inc. filed SEC Form 8-K: Completion of Acquisition or Disposition of Assets, Regulation FD Disclosure, Financial Statements and Exhibits8-K - Edgewise Therapeutics, Inc. (0001710072) (Filer)
- PREdgewise Therapeutics Completes Sale of Sevasemten for Up to $2.65 Billion, Strengthening Balance Sheet and Centering Company Focus on Cardiovascular Pipeline— Edgewise receives $1.55 billion in upfront cash and is eligible to receive up to $1.1 billion in regulatory and commercial milestones — — Transaction creates strategically focused cardiovascular company — — Upfront proceeds expected to fully fund EDG-7500 development through potential approval —BOULDER, Colo., July 13, 2026 /PRNewswire/ -- Edgewise Therapeutics, Inc. (NASDAQ:EWTX), a leading clinical-stage biopharmaceutical company focused on cardiovascular diseases, today announced the successful completion of its previously announced definitive agreement under which Servier, an independent international pharmaceutical group governed by a foundation, acquired sevasemten and Edgewise's mu
- PRServier completes the acquisition of Edgewise Therapeutics' Muscular Dystrophy BusinessAcquisition supports Servier's strategic ambition in rare neurology with sevasemten, a late-stage investigational treatment for Becker and Duchenne muscular dystrophies. The acquired asset and expert team strengthen Servier's commitment to innovate for patients with high unmet medical needs. SURESNES, France, July 13, 2026 /CNW/ -- Servier, an independent international pharmaceutical group governed by a foundation, today announced that it has completed the acquisition of the muscular dystrophy business of Edgewise Therapeutics Inc. (NASDAQ:EWTX), for up to $2.65 billion, including upfront payment of $1.55 billion as well as up to $1.1 billion in regulatory and commercial milestone payments
- ANALYSTOppenheimer initiated coverage on Edgewise Therapeutics with a new price targetOppenheimer initiated coverage of Edgewise Therapeutics with a rating of Outperform and set a new price target of $51.00
- INSIDERChief Scientific Officer Russell Alan J exercised 200,000 shares at a strike of $0.36 and sold $7,881,402 worth of shares (200,000 units at $39.41) (SEC Form 4)4 - Edgewise Therapeutics, Inc. (0001710072) (Issuer)
EWTX FAQ
7 questionsWhat does Edgewise Therapeutics Inc. do?
Edgewise Therapeutics, Inc., a biopharmaceutical company, develops small molecule therapies for musculoskeletal diseases. It offers a precision medicine muscle platform that generates programs to address various muscle disorders, such as Duchenne, Becker, and limb girdle muscular dystrophies. The company develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. Edgewise Therapeutics, Inc. was founded in 2017 and is headquartered in Boulder, Colorado.Where does EWTX stock trade?
Edgewise Therapeutics Inc. (EWTX) is listed on NASDAQ.What sector and industry is EWTX in?
Edgewise Therapeutics Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Edgewise Therapeutics Inc. go public?
Edgewise Therapeutics Inc. (EWTX) completed its IPO in 2021.What are analysts saying about EWTX?
Edgewise Therapeutics Inc. has had 8 recent analyst actions on file. The most recent action was from Oppenheimer: Outperform on 2026-07-09. Recent price targets range from $1400.00 to $4600.00.What companies are similar to EWTX?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare EWTX side-by-side with any of them on Quantisnow.How can I track EWTX on Quantisnow?
Quantisnow aggregates Edgewise Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow EWTX to receive live email and push alerts on every new disclosure.